Oxford Drug Design

Oxford Drug Design (ODD) operates as a preclinical biotechnology firm, originating as a spin-out from the University of Oxford in 2001. The company was founded by Professor Graham Richards, a seminal figure in computational chemistry, based on his pioneering work in the field at the university. The firm's leadership includes CEO Dr. Alan D. Roth, whose career spans medicinal chemistry at Merck, investment management, and co-founding a life sciences company, and CSO Dr. Paul Finn, with extensive experience in drug discovery at major pharmaceutical companies like Pfizer and GSK.

The core of ODD's business is a dual-competency discovery platform that combines generative AI and machine learning with deep expertise in aminoacyl-tRNA synthetase (aaRS) enzymes. This integrated approach is applied to design and develop novel small-molecule therapeutics. Initially focused on creating new antibiotics to combat multi-drug resistant infections, the company has more recently expanded into oncology, targeting unmet needs in lung and colorectal cancers. A recent in vivo mouse study for a colorectal cancer model demonstrated a 60% life extension, showing clear efficacy.

ODD's proprietary technology toolkit includes several key components. Its AI/ML capabilities are used to predict optimized molecular structures and biological activity before synthesis, significantly accelerating the discovery process. The 'EShape™' algorithm captures molecular shape and properties for rapid similarity searching at speeds of one million comparisons per second, mining the firm's curated 'CSpace™' database of approximately 6 million drug-like molecules. Furthermore, the company employs Topological Data Analysis (TDA) to extract unique features from molecules' 3D shapes, enriching its machine learning models. The business model has two primary streams: developing its own therapeutic pipeline and offering its computational platform as a commercial service to other pharmaceutical and biotechnology companies. This service is already generating revenue. To date, Oxford Drug Design has raised over $12 million in combined grant and equity funding through multiple rounds, with investors including ACF Investors, o2h Ventures, and R42 Group.

Keywords: AI drug discovery, computational chemistry, machine learning, oncology therapeutics, tRNA synthetase, small-molecule inhibitors, computer-aided drug design, drug-resistant infections, virtual screening, preclinical biotechnology, generative AI, topological data analysis, molecular modeling, chemogenomics, lead optimization, colorectal cancer, lung cancer, antibiotic resistance, proprietary platform, ligand-based design